Abstract
BackgroundThe incidence of malignancies in kidney transplant recipients is increasing. Breast cancer is a common malignancy after kidney transplantation and can be more aggressive in kidney transplant recipients than in the general population. In this study, we evaluated the incidence and prognosis of breast cancer in kidney transplant recipients.FindingsBetween 1993 and 2013, 750 kidney transplant patients were followed-up at our center. Since 1999, annual physical examination, mammography, and breast ultrasonography have been performed for such patients. Diagnostic studies, including core needle or mammotome biopsy, were performed for suspected malignancies. Patients with malignant neoplasm were administered the appropriate treatment and followed-up to assess tumor response and symptoms.Nine patients were diagnosed with breast cancer during the follow-up period. The mean age at the initial detection of the breast cancer was 47.7 ± 8.4 years. The mean interval from transplantation to diagnosis was 148.7 ± 37.1 months. Of the 9 patients, 8 were detected through the screening test; 7 were treated with breast conservative surgery and 1 was treated with modified radical mastectomy. The cancer stages were 0 (n = 2), I (n = 6), and II (n = 1). The incidence of breast cancer tended to be unchanged with time between transplantation and diagnosis, inconsistent with the increase in the duration of immunosuppression.ConclusionAnnual screening tests are crucial in the early diagnosis of breast cancer. Early treatment of breast cancer can result in an excellent prognosis in kidney transplant recipients.
Highlights
Advances in the development of immunosuppressive agents have significantly reduced the acute rejection rate and markedly improved graft survival in kidney transplantation (Meier-Kriesche et al 2004)
Annual screening tests are crucial in the early diagnosis of breast cancer
Treatment of breast cancer can result in an excellent prognosis in kidney transplant recipients
Summary
Advances in the development of immunosuppressive agents have significantly reduced the acute rejection rate and markedly improved graft survival in kidney transplantation (Meier-Kriesche et al 2004). Despite these encouraging trends, the long-term patient survival rate after kidney transplantation has remained unchanged (Webster et al 2008; Campistol 2009). The high mortality among kidney transplant recipients (KTRs) is attributed mainly to cardiovascular disease and malignancy (Campistol 2009). Breast cancer is a common malignancy after kidney transplantation and can be more aggressive in kidney transplant recipients than in the general population. We evaluated the incidence and prognosis of breast cancer in kidney transplant recipients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
